ESC 2021

2021 ESC Clinical Practice Guidelines

Best of the Hotline Sessions

Empagliflozin: First drug with clear benefit in HFpEF patients

Presented By

Prof. Stefan Anker, Charité University Hospital, Germany

Trial

Phase 3, EMPEROR-Preserved

Conference

ESC 2021

26 October, 2021 13:45

CardioMEMS: neutral outcome but possible benefit prior to COVID-19

Presented By

Prof. JoAnn Lindenfeld, Vanderbilt University Medical Center, USA

Trial

GUIDE-HF

Conference

ESC 2021

26 October, 2021 13:36

Cardiac arrest without ST-elevation: instant angiogram does not improve mortality

Presented By

Prof. Steffen Desch, University Heart Center Lübeck, Germany

Trial

TOMAHAWK

Conference

ESC 2021

26 October, 2021 13:32

Older hypertensive patients benefit from intensive blood pressure control

Presented By

Prof. Jun Cai, FuWai Hospital, China

Trial

STEP

Conference

ESC 2021

26 October, 2021 12:45

Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD

Presented By

Prof. Bertram Pitt, University of Michigan School of Medicine, USA

Trial

Phase 3, FIGARO-DKD

Conference

ESC 2021

26 October, 2021 12:40

Late-Breaking Science in Heart Failure

Late-Breaking Science in Hypertension

Late-Breaking Science in Prevention

NATURE-PCSK9: Vaccine-like strategy successful in lowering CV events

Presented By

Prof. Brian Ference, University of Cambridge, UK

Trial

NATURE-PCSK9

Conference

ESC 2021

26 October, 2021 16:19

Polypill: A successful tool in primary prevention

Presented By

Prof. Philip Joseph, McMaster University, Canada

Trial

TIPS-3; HOPE-3; Polylran

Conference

ESC 2021

26 October, 2021 15:58

Important Results in Special Populations

VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban

Presented By

Prof. Cecilia Low Wang, University of Colorado, USA

Trial

VOYAGER PAD

Conference

ESC 2021

26 October, 2021 16:24

COVID-19 and the Heart

ESC Spotlight of the Year 2021: Sudden Cardiac Death